Bioptimus Reaches $76M Funding Milestone as New AI Model Prepares for 2025 Launch
Deal News | Jan 14, 2025 | Cathay Capital
Bioptimus, a leader in AI foundation models for biology, announced a significant milestone of $76 million in funding, with a $41 million contribution led by Cathay Innovation. This financial boost follows the release of Bioptimus' initial AI model for pathology, which has shown exceptional results in predicting gene expressions and subtyping cancers. The new funding will accelerate Bioptimus' development of a transformative multi-modal AI model for biology, set to launch in 2025, which integrates various biological scales and modalities for deep insights into biological complexity. The model aims to transform medical and biotechnological research, enabling precise disease predictions and therapeutic designs. Bioptimus' initiatives are supported by a consortium of investors, including Sofinnova Partners, Bpifrance, and Hitachi Ventures, among others. This funding round underpins Bioptimus' mission to break down silos in biological understanding and leverage AI for unprecedented innovation across multiple industries.
Sectors
- Biotechnology
- Artificial Intelligence
- Venture Capital
Geography
- France – Bioptimus is based in Paris, France, and much of its development and operations occur here.
- Global – Cathay Innovation operates globally, investing in transformative businesses across continents.
Industry
- Biotechnology – Bioptimus is developing AI models to drive innovations in the biotech industry.
- Artificial Intelligence – The research and development of AI foundation models to simulate biological processes.
- Venture Capital – Cathay Innovation, a VC firm, is leading the investment in Bioptimus.
Financials
- $76 million – Total funding milestone reached by Bioptimus.
- $41 million – Latest cash injection led by Cathay Innovation.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Bioptimus | Target Company | Company | An AI foundation model company for biology, advancing scientific and biotech research. |
| Cathay Innovation | Bidding Company | Company | Venture capital firm leading the investment in Bioptimus for transformative AI innovations. |
| Sofinnova Partners | Investor | Company | A venture capital firm participating in the funding round. |
| Bpifrance through its Large Venture Fund | Investor | Company | A French public investment bank participating in the funding. |
| Andera Partners | Investor | Company | A private equity firm participating in the funding round. |
| Hitachi Ventures | Investor | Company | The corporate venture capital arm of Hitachi, investing in Bioptimus. |
| Boom Capital Ventures | Investor | Company | A venture capital firm participating in the funding. |
| Pomifer Capital | Investor | Company | A venture capital firm participating in the funding round. |
| Sunrise | Investor | Company | A venture capital firm involved in funding Bioptimus. |
| Emmanuel Cassimatis | Investor | Person | Angel investor involved in the funding round. |
| Thomas Wolf | Investor | Person | Angel investor participating in the investment. |